Intervention

Dostarlimab

ClinicalTrials.gov intervention label

Clinical trials16
Recruiting0
Common conditions25
Lead sponsors shown8

Clinical trials

16 shown
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)NCT06405230 · 2025-10-10
TERMINATED
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) PatientsNCT06879717 · 2025-04-22
ACTIVE_NOT_RECRUITING
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)NCT06472076 · 2024-06-10
ACTIVE_NOT_RECRUITING
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerNCT05565378 · 2022-10-14
ACTIVE_NOT_RECRUITING
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsNCT05277051 · 2022-03-22
ACTIVE_NOT_RECRUITING
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3NCT06926673 · 2021-12-23
COMPLETED
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal CancerNCT04673448 · 2021-10-18
ACTIVE_NOT_RECRUITING
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsNCT05060432 · 2021-09-06
UNKNOWN
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast CancerNCT04837209 · 2021-07-21
ACTIVE_NOT_RECRUITING
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine CarcinomasNCT04701307 · 2021-02-01
ACTIVE_NOT_RECRUITING
Niraparib + Dostarlimab In BRCA Mutated Breast CancerNCT04584255 · 2021-01-21
ACTIVE_NOT_RECRUITING
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and ChemotherapyNCT04655976 · 2020-12-08
ACTIVE_NOT_RECRUITING
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT04581824 · 2020-11-19
TERMINATED
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)NCT03739710 · 2019-01-24
COMPLETED
Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsNCT03250832 · 2017-08-08
COMPLETED
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsNCT02715284 · 2016-03-07
ACTIVE_NOT_RECRUITING

Common conditions

Lung Cancer, Non-Small Cell5Neoplasms5Breast Cancer2Advanced Cancer1Advanced Non Squamous NSCLC1Anatomic Stage III Breast Cancer AJCC v81Anatomic Stage IV Breast Cancer AJCC v81BRCA Hereditary Ovarian Carcinoma1BRCA-Associated Malignant Neoplasm1Deleterious PALB2 Gene Mutation1Germline BRCA1 Gene Mutation1Germline BRCA2 Gene Mutation1Head and Neck Cancer1HER2-negative Breast Cancer1Lung Cancer1Lung Small Cell Carcinoma1Melanoma1Metastatic BRCA Hereditary Breast Carcinoma1Metastatic Breast Carcinoma1Metastatic Fallopian Tube Carcinoma1Metastatic Malignant Solid Neoplasm1Metastatic Ovarian Carcinoma1Metastatic Pancreatic Carcinoma1Metastatic Primary Peritoneal Carcinoma1Neuroendocrine Carcinoma1

Trial status mix

ACTIVE_NOT_RECRUITING10
COMPLETED3
TERMINATED2
UNKNOWN1

Phase mix

PHASE211
PHASE17
PHASE32

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.